The pharmaceutical giant, whose China chief is now under investigation, was previously at the centre of insurance scam cases, ...

AstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line lung cancer trial – an indication where Merck ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

As AstraZeneca’s chronic obstructive pulmonary disease drug Breztri continues climbing toward blockbuster status, the Big Pharma is broadening its efforts to support people with COPD. | As AstraZeneca ...

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

The pharma giant confirmed that Wang Lei, the executive vice president who oversaw AstraZeneca’s rapid expansion in China, is ...

The drugmakers will explore the efficacy of Dato-DXd in combination with other drugs in PD-L1-expressing or EGFR-mutated NSCLC in these studies.

CNW/ - The 2025 Lung Ambition Awards – a Canadian-based lung cancer research award program – is now open for submissions. For ...

2024 AstraZeneca's Imfinzi Fails in Late-stage Trial to Treat Certain Lung Cancers AstraZeneca's blockbuster cancer drug Imfinzi has failed as a follow-up therapy to improve disease-free survival ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of ...

Dr. Goss has received research funding from AstraZeneca and Roche Pharmaceuticals and has served as a paid consultant or been on an Advisory Board for Amgen, AstraZeneca, Pfizer Inc., and Roche ...

while Orpathys is jointly developed by AstraZeneca and Hutchmed, and commercialised by Astra. Orpathys is approved in China for the treatment of patients with non-small cell lung cancer with MET ...